Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Â
Senology Newsletter - April 10, 2013
1. Senology Newsletter Page 1 of 3
Senology.org - Newsletter
International Senologic and Oncologic Scientific Community (ISOSC)Â
"Connecting specialists worldwide"
April 10, 2013
Editor-in-Chief: Gian Paolo Andreoletti, MD
Join us on LinkedIn, Twitter, Facebook, YouTube, ResearchGate, SlideShare, Flickr, and share comments.
Read Senology Newspaper daily
Senology collaborates with
Literature Selection
Kroenke CH et al.: "High- and Low-Fat Dairy Intake, Recurrence, and Mortality After Breast Cancer
Diagnosis", J Natl Cancer Inst. 2013 Mar 14. [Epub ahead of print]
Foca F et al.: "Decreasing incidence of late-stage breast cancer after the introduction of organized
mammography screening in Italy", Cancer. 2013 Mar 15 [Epub ahead of print]
Dawson SJ et al.: "Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer", N Engl J
Med. 2013 Mar 13. [Epub ahead of print]
Schindlbeck C et al.: "Comparison of circulating tumor cells (CTC) in peripheral blood and
disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients", J Cancer Res Clin
Oncol. 2013 Mar 23. [Epub ahead of print]
Harbeck N et al.: "Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American
Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision
making in node-negative breast cancer patients", Eur J Cancer. 2013 Mar 12 [Epub ahead of print]
Darby SC et al.: "Risk of ischemic heart disease in women after radiotherapy for breast cancer", N
Engl J Med. 2013 Mar 14;368(11):987-98
Donker M et al.: "Comparison of the sentinel node procedure between patients with multifocal and
unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: Identification rate and nodal
outcome", Eur J Cancer. 2013 Mar 19 [Epub ahead of print]
file://C:Documents and SettingsutenteDesktopSenology Newsletter.htm 09/04/2013
2. Senology Newsletter Page 2 of 3
Editorial
"Prognostic and predictive value of tumor-infiltrating lymphocytes in node-positive breast cancer",
Sherene Loi, Translational Breast Cancer Genomics Lab, Division of Research, Peter MacCallum Cancer
Centre, East Melbourne, Victoria, Australia
""We and others have previously shown that an immune signal can influence prognosis and response to
treatment, particularly “immunogenic therapies” in specific breast cancer subtypes, such as those estrogen
receptor (ER)-negative and/or overexpressing the HER2/neu oncogene. To validate this further and determine
immunity could be a clinically relevant biomarker, we evaluated the association between quantity of tumor
infiltrating lymphocytes (TILs) in a breast cancer, prognosis and prediction of response to anthracyline
chemotherapy in a large clinical trial in over 2000 primary breast cancers and long term follow-up data. We
found that TILs were strongly associated with a good prognosis in the triple negative breast cancer (TNBC:
ER, PGR, and HER2-negative) subtype - even node positive TNBCs had an excellent survival if they were
observed to have high amounts of TILs at diagnosis (read more)".
(Commentary on: Loi S et al.: "Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a
Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the
Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98", J Clin
Oncol. 2013 Jan 22. [Epub ahead of print])
Questions and Answers
Breast Surgery Workshop Summary - The Center for Natural Breast Reconstruction, Mount Pleasant, SC,
USA
Fragments of History
1976 - Gianni Bonadonna (Milan, Italy): "Our data indicate that patients with potentially curable breast cancer
and with positive axillary lymph nodes at the time of mastectomy show a statistically significant reduction in
recurrence rate during the first 27 months after radical mastectomy when treated with cyclic prolonged
combination chemotherapy. At present, the advantage of CMF appears statistically evident in all subgroups of
patients" (Bonadonna G et al.: "Combination chemotherapy as an adjuvant treatment in operable breast
cancer ", N Engl J Med. 1976 Feb 19;294(8):405-10)
Calendar of Events
5th IMPAKT Breast Cancer Conference, May 2-4, 2013, Brussels, Belgium
Precision Medicines in Breast Cancer, May 9-10, 2013, London, UK
15th Milan Breast Cancer Conference, June 20-21, 2013, Milan, Italy
3rd World Congress on Cancer Science & Therapy, October 21-23, 2013, San Francisco, CA, USA - in
partnership with Senology
9th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC), November 11-13,
Padova, Italy - under the Patronage of Senology
Update in Breast Imaging, 22-23 November, Ostend, Belgium
HEALTHCARE INDUSTRY NEWS
Bracco receives MHRA approval for expanded labeling of MultiHance
(gadobenate dimeglumine) in magnetic resonance imaging of the breast
Press release - Milan (Italy), March 11, 2013 - " Bracco receives MHRA approval for
expanded labeling of gadobenate dimeglumine in Magnetic Resonance Imaging of
the breast. - MultiHance, the highest relaxivity contrast agent for MRI of the central
nervous system, is now approved for breast MRI " (read more)
file://C:Documents and SettingsutenteDesktopSenology Newsletter.htm 09/04/2013